EGFR and colorectal carcinoma: Others who have investigated the consequences of targeting ADAM17 in pre-clinical CRC models have reported that ADAM17 regulates chemotherapy-induced activation of EGFR and ligand shedding, irrespective of the mutational status of KRAS [15].